【24h】

Development of perioperative glycemic control using an artificial endocrine pancreas

机译:使用人工内分泌胰腺的围手术期血糖控制的开发

获取原文

摘要

It is well known that tight glycemic control (TGC) in patients with diabetes mellitus is the most important to reduce complications, such as nephropathy, neuropathy, and retinopathy. Also, surgical stress induced hyperglycemia leading to glucose toxicity is the main cause of infectious complications after surgery. Recently perioperative TGC has been proven an effective method to reduce postoperative infectious complications and accelerate enhanced recovery after surgery (ERAS), with the main purpose of short staying hospital. However, conventional TGC with open-loop glycemic control system is likely to induce not only occurrence of hypoglycemia but also unstable glycemic control. To solve these problems, we have involved introduction of novel glycemic control using an artificial pancreas (AP) with closed-loop glycemic control system since 2006. To date, this novel perioperative glycemic control was performed in more than 400 surgical patients. As a result, we established stable and safe TGC using an AP to improve surgical outcomes without hypoglycemia. In this paper, we report current scientific evidence focusing on perioperative glycemic control using an AP.
机译:众所周知,糖尿病患者的严格血糖控制(TGC)对于减少并发症(如肾病,神经病和视网膜病)最重要。而且,手术应激引起的高血糖症导致葡萄糖毒性是手术后感染并发症的主要原因。最近,围手术期TGC已被证明是减少术后感染并发症并加速术后恢复(ERAS)的有效方法,其主要目的是短期住院。然而,具有开环血糖控制系统的常规TGC不仅可能引起低血糖的发生,而且可能引起不稳定的血糖控制。为了解决这些问题,自2006年以来,我们已采用人工胰腺(AP)与闭环血糖控制系统进行新型血糖控制。迄今为止,这种新型围手术期血糖控制已在400多名手术患者中进行。结果,我们使用AP建立了稳定且安全的TGC,可改善手术效果而无低血糖症。在本文中,我们报告了当前有关使用AP围手术期血糖控制的科学证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号